Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes

L Bataller, K A Kleopa, G F Wu, J E Rossi, M R Rosenfeld, J Dalmau

Background: About 40% of patients with limbic encephalitis do not have detectable CNS antibodies. Some of these patients have immune-mediated limbic encephalitis, but their frequency is unknown.

Aims: (1) To determine the spectrum of limbic encephalitis identified on clinical grounds in a single institution, and compare it with that in patients referred for antibody analysis. (2) To correlate clinical outcomes with the cellular location of the autoantigens.

Methods: Prospective clinical case studies. Immunohistochemistry with rat brain, live hippocampal neurons, HeLa cells expressing Kv potassium channels and immunoblot.

Results: In 4 years, 17 patients were identified in the Hospital of the University of Pennsylvania, Philadelphia, USA, and the serum or CSF samples of 22 patients diagnosed elsewhere were also studied. 9 of our 17 (53%) patients had antibodies to known neuronal antigens (paraneoplastic or voltage gated potassium channels (VGKCs)) and 5 (29%) to novel cell-membrane antigens (nCMAg) typically expressed in the hippocampus and sometimes in the cerebellum. Considering the entire series, 19 of 39 (49%) patients had antibodies to known antigens, and 17 (44%) to nCMAg. Follow-up (2–48 months, median 19 months) was available for 35 patients. When compared with patients with antibodies to intraneuronal antigens, a significant association with response to treatment was found in those with antibodies to cell-membrane antigens in general (VGKC or nCMAg, p = 0.003) or to nCMAg (p = 0.006).

Conclusions: (1) 82% of patients with limbic encephalitis prospectively identified on clinical grounds had CNS antibodies; (2) responsiveness to treatment is not limited to patients with VGKC antibodies; (3) in many patients (29% from a single institution), the autoantibodies were unknown but were found to be highly enriched in neuronal cell membranes of the hippocampus; and (4) these antibodies are associated with a favourable outcome.

Until the mid-1990s, most cases of non-viral limbic encephalitis were considered to be paraneoplastic. However, there are an increasing number of reports of patients whose clinical, radiological and CSF findings suggest limbic encephalitis but whose diagnostic tests and follow-up exclude an underlying cancer. Evidence that some of these disorders are immune mediated includes the recent description of limbic encephalitis associated with antibodies to voltage-gated potassium channels (VGKC), the occasional association with systemic autoimmune disorders and frequent response to immunotherapy. Recent studies show that in addition to anti-VGKC, there are other limbic encephalitis-related antibodies that target novel cell-membrane antigens (nCMAg). These findings have broadened the spectrum of limbic encephalitis and suggest extensive antigen diversity. The relative frequency of these disorders is unknown because they are often unrecognised or have been excluded from most series of limbic encephalitis whose inclusion criteria are limited to patients with specific types of tumors or antibodies. Also, there is no single prospective institutional study reporting clinical experience with all of these disorders.

In this study, we review the clinical types and immunophenotypes of 39 patients with limbic encephalitis studied in the past 4 years, focusing on the relative distribution of patients seen by us in a single institution (n = 17) and those whose serum or CSF was referred to us for antibody analysis (n = 22). We also examine the clinical implications of identifying antibodies to known antigens and nCMAg.

METHODS

This study included patients who were seen by us between January 2002 and January 2006 at the Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA, and patients whose clinical information, MRI scans, and sera or CSF samples were sent to us for consultation concerning a recent onset disorder (<12 weeks’ duration) consistent with focal limbic encephalitis or multifocal encephalitis with predominant symptoms of limbic dysfunction. These included confusion, seizures, short-term memory loss or psychiatric symptoms in association with one or more of the following: (1) neuroimaging (MRI or positron emission tomography) evidence of temporal lobe involvement; (2) CSF inflammatory abnormalities (pleocytosis, increased protein concentration or oligoclonal bands); or (3) detection of antibodies that occur in association with limbic encephalitis. All patients were examined for systemic cancer using whole-body computed tomography or fluorodeoxyglucose-positron emission tomography, and studied for autoimmune disorders with the following tests: antinuclear antibody, anti-double-stranded DNA, Smith/Rnp, Sjogren’s (SSA,SSB), anti-neutrophilic cytoplasmic antibodies, antidiolipin, antithyro-globulin and antimicrosomal (thyroperoxidase) antibodies. Patients with CNS infection or metastases were excluded from analysis. Eleven cases have been reported previously. All studies were approved by the University of Pennsylvania institutional review board. Fisher’s exact test was used in statistical analyses.

Analysis of CNS antibodies

Serum and CSF samples were available from 35 patients; only serum or CSF was available from two patients each.

Abbreviations: CNS, central nervous system; HUP, Hospital of the University of Pennsylvania; MRI, magnetic resonance imaging; nCMAg, novel cell-membrane antigen; VGKC, voltage-gated potassium channel
Immunohistochemistry was performed using previously reported methods on the following: (1) rat brain sections fixed with acetone or methanol-acetone (serum 1:500; CSF 1:10) 14; (2) rat brain sections pre-fixed with paraformaldehyde (PFA) (serum 1:250; CSF 1:10); and (3) live rat hippocampal neuronal cultures (serum 1:1000; CSF 1:50). Additional studies included immunoblot with proteins extracted from purified human neurones, and recombinant HuD, Ma1 and Ma2, CRMP5 and amphiphysin. 15 The presence or absence of VGKC was confirmed by radioimmunoassay at Athena Diagnostics (Worcester, MA, USA), and with transfected HeLa cells expressing Kv1.1, Kv1.2, Kv1.4 and Kv1.6 VGKC subunits as reported recently. 16

RESULTS
Antibodies
In all, 39 patients were identified with limbic encephalitis: 17 were seen at the HUP and 22 at other institutions. Table 1 shows the associated antibodies, methods used to demonstrate them and the location of the antigens. Fourteen patients had antibodies to intraneuronal antigens (anti-Hu, n = 7; anti-Ma2, n = 6; and unknown, n = 1) and all were identified with standard immunohistochemistry with methanol-acetone-fixed tissue (fig 1A) or immunoblot studies. Five patients had anti-VGKC, demonstrated by immunohistochemistry with PFA-fixed tissue and radioimmunoassay (range 195–621, median 320; positive >173 pmol). Seventeen patients had novel antibodies that were detected only with immunohistochemistry with PFA-fixed tissue (fig 1B) and cultures of live hippocampal rat neurones (all with intense immunolabelling of cell membrane antigens; nCMAg; fig 1C,D). The patterns of rat brain immunolabelling of these antibodies have been reported previously: nine were highly restricted to the neuropil of hippocampus (all patients with ovarian teratoma), 8 and six had additional reactivity with the molecular layer of the cerebellum and to a lesser degree of the cerebral cortex. 7 Three patients had no detectable antibodies.

Of the five patients with VGKC antibodies, three were seen at the HUP and underwent additional examinations to determine which specific Kv subunits were targeted by the antibodies. One patient had antibodies to Kv1.1, another to Kv1.1 and Kv1.2, and the third to Kv1.1 and Kv1.6.

All serum or CSF samples of 17 patients with anti-nCMAg were negative by the radioimmunoassay, although one showed mild reactivity with cells expressing Kv1.4 (data not shown) and another with cells expressing Kv1.6 (both patients had encephalitis associated with ovarian teratoma). Both these samples produced an identical pattern of hippocampal

<table>
<thead>
<tr>
<th>Table 1 Antibodies, methods of detection and antigen location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Occurrence of antibodies</td>
</tr>
<tr>
<td>---------------------------</td>
</tr>
<tr>
<td>Characterised antibodies, n = 19</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Partially characterised antibodies, n = 17</td>
</tr>
<tr>
<td>No antibodies, n = 3</td>
</tr>
</tbody>
</table>

IC, immunocytochemistry; IH: immunohistochemistry; nCMAg, novel cell-membrane antigen; PFA, paraformaldehyde.
immunolabelling that was clearly different from that obtained with polyclonal Kv1.4 or Kv1.6 antibodies, indicating that the main targets were other (unknown) hippocampal antigens. None of the antibodies to nCMAg of the other 15 patients reacted with cells expressing any of the indicated Kv subunits.

All antibodies (including anti-VGKC) were identified in the serum and CSF (if available). However, antibodies to nCMAg were technically easier to detect in the CSF than in serum. In 3 of 17 patients with antibodies to nCMAg, the initial studies demonstrated the antibodies only in the CSF; in all the three cases repeat studies with concentrated sera (dilution 1:100) showed the hippocampal neuropil reactivity over diffuse background staining. This background staining was similar to that found in normal control sera when used at a 1:100 dilution in PFA-fixed tissue. No background staining occurred with the CSF of patients or controls.

CLINICAL–IMMUNOLOGICAL FEATURES

Table 2 shows the clinical and immunological features of the 17 patients seen at the HUP. Of these 17 patients, two were referred from other institutions to one of the authors on suspicion of a paraneoplastic disorder; the other 15 patients were diagnosed during their admission for neurological symptoms of unknown aetiology (n = 12) or in the outpatient clinic (n = 3). None of these 15 patients was specifically referred to the HUP or any of the authors for a paraneoplastic disorder. We included six patients with antibodies to intracellular antigens (anti-Hu, n = 4; anti-Ma2, n = 1; and atypical antibodies, n = 1), eight with antibodies to neuronal cell-membrane antigens (to nCMAg, n = 5 and to VGKC, n = 3), and three without detectable antibodies.

During the same period, we received clinical information, sera or CSF samples of 22 patients with limbic encephalitis from other institutions (table 3). These studies resulted in the identification of patients with antibodies to intracellular antigens (n = 8; Hu, n = 3; Ma2, n = 5), nCMAg (n = 12) and VGKC (n = 2).

EXPERIENCE AT A SINGLE INSTITUTION: COMPARISON WITH REFERRED CASES

Comparing the immunophenotypes of patients seen at the HUP with the referred cases, the two main differences were: (1) the relatively lower frequency of patients with antibodies to Ma2 (7%) and to nCMAg (36%) at the HUP compared with the referrals (23% with antibodies to Ma2 and 55% to nCMAg), and (2) the younger age of the patients in this referral group, in which the main tumours were germ-cell neoplasm of the testes (n = 4; age 23–36, median 25 years) and ovarian teratoma (n = 8; age 14–40, median 29 years), both histological types typically occurring in young patients (tables 2, and 3).

OVERVIEW OF IMMUNOPHENOTYPES

The main differences among immunophenotypes of all 39 patients were as follows:

1. The high frequency of abnormal movements (41%) and decreased level of consciousness and hypoventilation (59%) in patients with nCMAg
2. The tumour associations: 90% of patients with antibodies to intracellular autoantigens had tumours of the lung or testes, 76% of patients with antibodies to nCMAg had teratomas or tumours of the thymus, and only 20% of patients with VGKC had a tumour
3. The low frequency of “typical” limbic or medial temporal lobe hyperintensities in MRI T2 or fluid attenuation inversion recovery in patients with antibodies to nCMAg (35%) when compared with patients with antibodies to intracellular antigens (57%) or anti-VGKC (100%)
4. The better clinical outcome in patients with antibodies to nCMAg and VGKC.

TREATMENT AND CLINICAL OUTCOME

Clinical information and adequate follow-up was obtained from 35 patients. Of 29 patients with tumours, five did not receive

---

**Table 2**

<table>
<thead>
<tr>
<th>Total patients (antigens)</th>
<th>Sex; age range (median), years</th>
<th>Other neurological features or symptoms</th>
<th>CSF findings, range (median)</th>
<th>Typical &quot;limbic&quot; MRI abnormality</th>
<th>Cancer</th>
<th>Immunotherapy other than corticosteroids</th>
<th>Neurological outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hu, n = 4; Ma2, n = 1; typical, n = 1</strong></td>
<td>5M, 1F; 28–65 (63)</td>
<td>Encephalomyelitis, n = 2; sensory neuronopathy, n = 3; cerebellar/ or brainstem, n = 2</td>
<td>WBC 0–81 (3); PtProt 74–150 (79)</td>
<td>Typical, n = 2; other, n = 2</td>
<td>SCCL, n = 4; testicular, n = 1; thyroid, n = 1</td>
<td>IVIg, n = 1; CTX, n = 2; IVIg-PEX +Rituximab, n = 1</td>
<td>PI (Ma2), n = 1; stable (Hu), n = 1; died, n = 4</td>
</tr>
<tr>
<td><strong>nCMAg, n = 5</strong></td>
<td>5F, 24–65 (44)</td>
<td>Diffuse encephalitis, n = 2; decreased level of consciousness and hyperventilation, n = 1; chorea/dystonia, n = 1</td>
<td>WBC 15–49 (30); Prot 18–97 (67)</td>
<td>❌Other, n = 4; normal, n = 1</td>
<td>Teratoma, n = 3 (ovary, n = 2; thymus, n = 1); cancer of thymus, n = 1; no tumour, n = 1</td>
<td>IVIg, n = 1; PEX, n = 1</td>
<td>CI (n = 4, teratoma, n = 3, cancer of thymus, n = 1); deteriorated (no tumour), n = 1</td>
</tr>
<tr>
<td><strong>VGKC, n = 3</strong></td>
<td>2M, 1F; 38–60 (58)</td>
<td>Peripheral nerve hyperexcitability, n = 1</td>
<td>WBC 0–4 (2); Prot 45–79 (63)</td>
<td>Typical, n = 3</td>
<td>Prostate, n = 1</td>
<td>IVIg, n = 2</td>
<td>CI, n = 2; stable, n = 1</td>
</tr>
<tr>
<td><strong>No antibodies, n = 3</strong></td>
<td>1M, 2F; 28–60 (40)</td>
<td>Multiple (cerebellar myelopathy neuropathy, n = 1)</td>
<td>WBC 2–119 (10); Prot 32–132 (47)</td>
<td>Typical, n = 2; other, n = 1</td>
<td>Prostate, n = 1</td>
<td>Aza, n = 1</td>
<td>CI, n = 3</td>
</tr>
</tbody>
</table>

Aza, azathioprine; CI, complete improvement; CTX, cyclophosphamide; F, female; IVIg, intravenous immunoglobulin; M, male; nCMAg, novel cell-membrane antigen; PI, partial improvement; PEX, plasma exchange; SCCL, small-cell lung cancer; VGKC, voltage -gated potassium channels; WBC, white blood cells.

*WBC (white cell count) per μl; normal value <4/μl.
†Prot (protein concentration) in mg/dl; normal value 16–46 mg/dl.
‡Other: fluid attenuation inversion recovery or T2 abnormalities in regions other than medial temporal lobes.
Table 3  Clinical features and immunological findings in patients with limbic encephalitis seen at other institutions (n = 22)

<table>
<thead>
<tr>
<th>Total patients (antigen)</th>
<th>Sex, age range (median)</th>
<th>Other neurological features or symptoms</th>
<th>CSF finding range (median)</th>
<th>Typical &quot;limbic&quot; MRI abnormality</th>
<th>Cancer</th>
<th>Immunotherapy other than corticosteroids</th>
<th>Neurological outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hu, n = 3; Ma2, n = 5</td>
<td>6M, 2F; 23–67 (36)</td>
<td>Encephalomyelitis, n = 1; brainstem, n = 2; hypothalamic, n = 1</td>
<td>WBC 2–20 (18); Prot 30–747 (80)</td>
<td>Typical, n = 4; other, n = 3; NA, n = 1</td>
<td>SCCL, n = 3; non-SCCL, n = 1; testicular, n = 4</td>
<td>PEX, IVlg, n = 1; PEX, n = 1; IVlg, n = 3</td>
<td>PI (Ma2), n = 1; Cl (Hu), n = 1; stable (Ma2), n = 1; died (Ma2), n = 2; Hu, n = 1; n = 3; no follow-up, n = 2</td>
</tr>
<tr>
<td>nCMAg, n = 12</td>
<td>2M, 1OF; 3–40 (29)</td>
<td>Decreased level of consciousness and hypoventilation, n = 9; dystonia/ choreoathetosis, n = 6; stiff-person, n = 1</td>
<td>WBC 7–189 (20); Prot 30–92 (50)</td>
<td>Typical, n = 6; other, n = 4; normal, n = 2</td>
<td>Thymoma, n = 1; teratoma of the ovary, n = 8; no tumour, n = 1; not known, n = 2</td>
<td>PEX, n = 3; IVlg, n = 2; PEX, IVlg, n = 2; PEX, IVlg + CTX, n = 2</td>
<td>PI, ovarian teratoma, n = 3; thymoma, n = 1; no tumour, n = 1; n = 5; CI (ovarian teratoma), n = 3; no follow-up, n = 2</td>
</tr>
<tr>
<td>VGKC, n = 2</td>
<td>2M, 58 and 59</td>
<td>–</td>
<td>WBC 0–2; Prot normal</td>
<td>Typical, n = 2</td>
<td>No cancer</td>
<td>PEX, n = 1; IVlg, n = 1</td>
<td>CI (relapsing syndrome), n = 1</td>
</tr>
</tbody>
</table>

CI, complete improvement; CTX, cyclophosphamide; F, female; IVlg, intravenous immunoglobulin; M, male; NA, not available; nCMAg, novel cell-membrane antigen; PEX, plasma exchange; PI, partial improvement; SCCL, small-cell lung cancer; VGKC, voltage-gated potassium channels.

WBC (white blood count) per µl, normal value 16–46 mg/dl.

Prot (protein concentration) in mg/dl, normal value 0.16–46 mg/dl.

Oncoligic therapy (small-cell lung cancer, n = 2; teratomas, n = 3); four of these patients died of neurological progression and one (ovarian teratoma) recovered after receiving corticosteroids and intensive care support. The other 24 patients had oncological therapy (tumour resection, n = 18; chemotherapy, n = 3; both, n = 1). All 35 patients received corticosteroids, 10 intravenous immunoglobulin, 6 plasma exchange, 7 intravenous immunoglobulin and plasma exchange (3 also received other immunosuppressants), 2 cyclophosphamide and 1 azathioprine.

The median follow-up was 19 (range 2–48) months. These patients were considered to be completely improved if they were able to return to work or normal daily activities. Patients were considered to be partially improved if they were not able to return to work but could function independently at home or return to most of their daily activities. In all, 22 patients had neurological improvement (tables 2, and 3); 3 with antibodies to intracellular antigens (Ma2, n = 2; Hu, n = 1), 12 to nCMAg, 4 to VGKC and 3 without antibodies. Of these 22 patients, 15 (Hu, n = 1; nCMAg, n = 7; VGKC, n = 4; no antibodies, n = 3) completely improved and the other seven partially improved. Of the 13 patients who had clinical stabilisation (n = 3) or deterioration (n = 10), 9 had antibodies to intracellular antigens, 3 to nCMAg and 1 to VGKC. When compared with patients with antibodies to intracellular antigens, those with antibodies to cell-membrane antigens in general (including nCMAg and VGKC) were more likely to have neurological improvement (p = 0.003). A similar strong association with improvement was found in the subgroup of patients with antibodies to nCMAg (p = 0.006).

**DISCUSSION**

In the past 4 years, we prospectively identified 17 patients with limbic encephalitis in a single institution. A remarkable finding is that 9 (53%) of these patients had antibodies to previously known antigens and 5 (29%) to nCMAg. Considering these patients and those whose serum or CSF samples were sent to us for analysis, 19 of 39 (49%) patients had antibodies known to be associated with limbic encephalitis (paraneoplastic or VGKC). However, 17 of 39 (44%) patients had antibodies to diverse nCMAg that are not measured by currently available commercial tests and were not included in the recently reported diagnostic criteria of paraneoplastic syndromes. This finding is important because the disorders associated with cell-membrane antigens in general (either VGKC or nCMAg) are usually responsive to treatment and have a definitely better prognosis than those associated with intracellular antigens. Correlation between antibody titres and improvement was not determined in this study, partly because the nCMAg antibodies are predominantly found in the CSF and repeat spinal taps were not obtained after improvement in these patients.

A review of a previous series of patients with autoimmune limbic encephalitis shows that most did not adequately reflect the clinical–immunological spectrum of the disorder because of the following:

1. Cases were identified from retrospective review of patients known to have cancer
2. Laboratories tested sera or CSF samples selected at multiple institutions
3. The inclusion criteria were restricted to patients with a specific type of cancer or antibody

None of these biases pertains to the 15 patients in our study who were identified on clinical grounds at the HUP and who provide a relative distribution of immunophenotypes in limbic encephalitis.

However, a referral bias was noted in the 22 patients whose sera or CSF samples were sent to us for analysis. The referral pattern seemed to be driven by our recent reports on subtypes of limbic encephalitis. Of the 22 patients, 17 (77%) had anti-Ma2 (23%) or antibodies to nCMAg (54%). By contrast, the frequency of anti-Ma2 encephalitis in patients in HUP was markedly lower (6%), while the occurrence of limbic encephalitis with antibodies to nCMAg was found more frequently than anti-VGKC (18%), suggesting that many patients who are considered to have idiopathic or “non-herpetic limbic encephalitis without VGKC antibodies” may indeed have antibodies to nCMAg.
immunophenotypes reported here; and (2) all samples from patients without antibodies to intracellular antigens were examined for anti-VGKC using at least two and in some cases three different methods (radioimmunoassay, immunohistochemistry with brain tissue, and immunocytochemistry with cells expressing Kv subunits). Although the five patients with anti-VGKC were positive by all methods used (three patients examined with all three methods), the 17 patients with antibodies to nCMAg were negative by all methods, except for two patients who showed faint reactivity with cells expressing Kv1.4 and Kv1.6 in the other. In both instances, the reactivity with brain was clearly different from the reactivity with two patients who showed faint reactivity with cells expressing Kv1.4 and Kv1.6 antibodies (data not shown), indicating that the presence of antibodies to other antigens was more restricted to the hippocampus. In previously reported instances, the reactivity with brain was clearly different from that reported here.

These findings have important clinical implications:

1. Besides the known antibodies associated with limbic encephalitis (paraneoplastic or VGKC), there is an emerging group of patients with treatment-responsive limbic encephalitis.

2. These disorders are associated with antibodies that predominantly react with the neuropil of the hippocampus and may occur without or with a tumour association.

3. Among all subphenotypes, there is a group of young women who have apparently benign ovarian cysts, but pathological studies show mature or immature teratoma. The importance of recognising these patients is that they may transiently improve with immunotherapy, but preliminary experience suggests that recovery depends on both tumour removal and immunotherapy10–12 (manuscript in preparation).

4. At presentation, there are no neurological, MRI or CSF features specific of any immunophenotype, except for the predominant type of tumour in some paraneoplastic disorders (ie, Ma2 and testicular cancer; Hu and small-cell lung cancer), or the low likelihood of cancer in patients with anti-VGKC.4,10

The generally favourable outcome in most patients with antibodies to cell-membrane antigens (either VGKC or nCMAg) validates a previously suggested approach for the management of patients with limbic encephalitis. After reasonable exclusion of other disorders (ie, herpes simplex virus encephalitis was diagnosed in 26 patients during the same 4-year period at the HUP), patients suspected of having autoimmune limbic encephalitis should be considered for immunotherapy (corticosteroids, intravenous immunoglobulin or plasma exchange). Treatment should start even in the absence of antibody testing because patients with limbic encephalitis-VGKC or ovarian teratoma can deteriorate rapidly, with status epilepticus, hyponatraemia or hyperventilation that may result in death. Also, some patients with limbic encephalitis of unclear aetiology or without antibodies may show dramatic response to corticosteroids, as found in three of our patients.

ACKNOWLEDGEMENTS

We thank all the doctors at the Hospital of Pennsylvania, particularly the Neurology residents, for their thorough evaluations and awareness of paraneoplastic neurological disorders; and Dr Erdem Tüzün for critically reviewing the manuscript. We also thank the doctors who provided clinical information on patients diagnosed at other institutions.

Authors’ affiliations

I Bataller, G F Wu, J E Rossi, M R Rosenfeld, J Dalmau, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA

K A Kleopa, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus

Funding: This study was supported in part by grants RO1CA89054 and RO1CA107192 (to JD) and a National Multiple Sclerosis Society grant (to KD).

Competing interests: None declared.

REFERENCES


www.jnnp.com

Downloaded from http://jnnp.bmj.com/ on October 1, 2017 - Published by group.bmj.com
Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes

L Bataller, K A Kleopa, G F Wu, J E Rossi, M R Rosenfeld and J Dalmau

*J Neurol Neurosurg Psychiatry* 2007 78: 381-385 originally published online September 15, 2006
doi: 10.1136/jnnp.2006.100644

Updated information and services can be found at:
http://jnnp.bmj.com/content/78/4/381

These include:

**References**
This article cites 22 articles, 2 of which you can access for free at:
http://jnnp.bmj.com/content/78/4/381#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Infection (neurology) (494)
- Brain stem / cerebellum (670)
- Immunology (including allergy) (1943)
- Editor's choice (139)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/